REGENXBIO Inc. financial data

Symbol
RGNX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
9804 Medical Center Drive, Rockville, Maryland
Fiscal year end
December 31
Former names
ReGenX Biosciences, LLC (to 11/7/2013)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 304 % -14.5%
Debt-to-equity 71.2 % +24.7%
Return On Equity -70.7 % -42.3%
Return On Assets -41.3 % -30.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.3M shares +13.3%
Common Stock, Shares, Outstanding 49M shares +12.8%
Entity Public Float 805M USD -18.3%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 45.7M shares +5.25%
Weighted Average Number of Shares Outstanding, Diluted 45.7M shares +5.25%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 86.7M USD -20.9%
Research and Development Expense 229M USD -6.83%
General and Administrative Expense 84.2M USD -1.69%
Costs and Expenses 353M USD -3.97%
Operating Income (Loss) -266M USD -3.23%
Nonoperating Income (Expense) 5.53M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -264M USD +5.98%
Income Tax Expense (Benefit) -152K USD -81%
Net Income (Loss) Attributable to Parent -260M USD +3.75%
Earnings Per Share, Basic -5.87 USD/shares +5.93%
Earnings Per Share, Diluted -5.87 USD/shares +5.93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 113M USD +61.2%
Marketable Securities, Current 226M USD -13.8%
Cash, Cash Equivalents, and Short-term Investments 381M USD -19.6%
Accounts Receivable, after Allowance for Credit Loss, Current 15.8M USD -16.1%
Other Assets, Current 27.3M USD +18.7%
Assets, Current 395M USD +1.6%
Property, Plant and Equipment, Net 128M USD -9.83%
Operating Lease, Right-of-Use Asset 57.6M USD -9.68%
Other Assets, Noncurrent 4.22M USD -49.1%
Assets 629M USD -15.9%
Accounts Payable, Current 31.4M USD +34.7%
Employee-related Liabilities, Current 8.09M USD -6.83%
Contract with Customer, Liability, Current 13K USD -99%
Liabilities, Current 110M USD -1.92%
Operating Lease, Liability, Noncurrent 80.2M USD -7.83%
Other Liabilities, Noncurrent 3.49M USD -41.8%
Liabilities 239M USD -15.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.23M USD +72.2%
Retained Earnings (Accumulated Deficit) -768M USD -51.2%
Stockholders' Equity Attributable to Parent 391M USD -16%
Liabilities and Equity 629M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.5M USD +31.5%
Net Cash Provided by (Used in) Financing Activities 121M USD
Net Cash Provided by (Used in) Investing Activities 13.2M USD -79.1%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 49M shares +12.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 78.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 115M USD +59.5%
Deferred Tax Assets, Valuation Allowance 280M USD +32.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 324M USD +24.9%
Operating Lease, Liability 89.3M USD -5.81%
Payments to Acquire Property, Plant, and Equipment 557K USD -88.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -252M USD +6.74%
Lessee, Operating Lease, Liability, to be Paid 122M USD -8.02%
Property, Plant and Equipment, Gross 189M USD +1%
Operating Lease, Liability, Current 7.07M USD +12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.8M USD +3.94%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.9M USD +5.33%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33M USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +1.43%
Deferred Tax Assets, Operating Loss Carryforwards 61.9M USD +143%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -152K USD -81%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 100K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10M USD -19.2%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) -152K USD -74.7%
Current Federal Tax Expense (Benefit) 3K USD -99.9%
Deferred Tax Assets, Net of Valuation Allowance 43.3M USD -9.91%
Share-based Payment Arrangement, Expense 38.7M USD -6.14%
Interest Expense 6.08M USD -69.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%